Aptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$11.11 and traded as low as C$5.39. Aptose Biosciences shares last traded at C$5.46, with a volume of 708 shares traded.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th.

Aptose Biosciences Trading Up 0.9 %

The stock has a market cap of C$235.10 million, a price-to-earnings ratio of -1.09 and a beta of 1.36. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The business has a 50-day moving average of C$7.27 and a 200-day moving average of C$11.11.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.